CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program.

The CAP Laboratory Accreditation Program is internationally recognized as the "gold standard" in laboratory accreditation. As part of this distinction, CNSide Diagnostics' laboratory underwent a rigorous on-site inspection evaluating clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, safety programs, and overall laboratory management. CNSide Diagnostics now joins more than 8,000 CAP-accredited laboratories worldwide.